Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03461783 · ClinicalTrials.gov registry record · NA

Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

A NA study of Wound Infection, sponsored by Brock Liden, DPM.

Completed
Registry status
NA
Development phase
21
Enrollment target
2
Study locations

NCT03461783 is a NA study of Wound Infection that has completed, run by Brock Liden, DPM. The registered enrollment target is 21 participants, below the 376-participant average among 10 other Wound Infection trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03461783, a NA study of Wound Infection, has completed, sponsored by Brock Liden, DPM.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this randomized, prospective study is to evaluate how this activated carbon dressing affects the total bacterial load and biofilm in a wound bed in wounds of the lower extremity and foot. We anticipate that the use of Zorflex® Activated Carbon Cloth dressing will maintain the bacterial burden in the wound bed below the level of critical colonization, with potential secondary benefits of pain reduction, decrease in inflammation, and control of odor. Wound bed healing progression/acceleration also will be assessed.

Conditions Studied

Interventions

  • DEVICE Standard of Care
  • DEVICE Zorflex Activated Carbon Dressing

Study Locations (2)

Ohio

  • Circleville Foot & Ankle, LLC - Circleville
  • Hocking Valley Community Hospital - Logan

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2017-06-26
Est. Completion 2019-02-01
Phase NA

Sponsor

Brock Liden, DPM

1 total trials

What the Registry Record Tells You About NCT03461783

The ClinicalTrials.gov registry entry for NCT03461783 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 10 other Wound Infection trials with a reported enrollment target (94% lower). The listed sponsor is Brock Liden, DPM, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Wound Infection appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT03461783 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03461783 about?

NCT03461783 is a clinical study titled "Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load". The purpose of this randomized, prospective study is to evaluate how this activated carbon dressing affects the total bacterial load and biofilm in a wound bed in wounds of the lower extremity and foot. We anticipate that the use of Zorflex® Activated Carbon Cloth dressing will maintain the bacteria...

What is the current status of trial NCT03461783?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2017-06-26. Estimated completion is 2019-02-01.

What conditions does trial NCT03461783 study?

This clinical trial studies the following conditions: Wound Infection.

What interventions are being tested in trial NCT03461783?

The interventions under investigation include: Standard of Care (DEVICE), Zorflex Activated Carbon Dressing (DEVICE).

Who is sponsoring clinical trial NCT03461783?

This trial is sponsored by Brock Liden, DPM, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03461783 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wound Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.